How much does a box of Capmatinib cost under medical insurance?

Capmatinib is a highly selective MET inhibitor developed by Novartis. It is mainly used to treat patients with non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping mutations. This mutation causes abnormal activation of the MET protein, thereby promoting tumor growth and spread. By blocking the MET signaling pathway, capmatinib can significantly inhibit the proliferation of tumor cells and delay or prevent the progression of the disease. This drug has become an important choice for the treatment of this specific population due to its precise targeting and good clinical efficacy.

Currently, capmatinib has not yet been officially launched in mainland China, so domestic patients cannot purchase the original drug through formal channels. Foreign original drugs are more expensive, with a box usually costing tens of thousands of yuan. The specific price varies by region. In contrast, the prices of generic drugs produced abroad are relatively affordable, especially those in Laos and India, which cost around 3,000 yuan and have basically the same efficacy as the original drugs. This provides more options for patients with limited financial resources.

Capmatinib has not yet been included in the medical insurance list in mainland China, so it is a self-paid drug for domestic patients. This makes its treatment more expensive, especially the price of the original drug. If patients want to obtain capmatinib treatment, they usually need to purchase drugs overseas or seek generic drugs as alternatives. In the future, as capmatinib gradually enters the Chinese market, it is expected to be included in medical insurance through negotiations, further reducing the financial burden on patients.

For patients who need to use capmatinib, genetic testing should be performed according to the guidance of the doctor to determine whether there is aMETexon14 skipping mutation. This precise diagnosis helps improve the effectiveness of treatment and avoids unnecessary use of medications. At the same time, patients need to regularly monitor the treatment effects and adverse reactions during use to ensure the safety and continuity of treatment.

As a new type of targeted drug, capmatinib has shown great potential in the treatment ofMET related lung cancer. With further promotion and research of the drug, its scope of application may be expanded to other types of tumors. At the same time, the widespread use of generic drugs and market competition may further reduce treatment costs and benefit more patients.

xa0

Reference materials

Novartis official website:https://www.novartis.com